The correct name for dabigatran is dabigatran ester, a small molecule precursor drug that is hydrolyzed to dabigatran by esterases and is a direct thrombin anticoagulant. It acts to prevent thrombosis by inhibiting thrombin. It prevents stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation, treats deep vein thrombosis or prevents its recurrence, and treats pulmonary embolism or prevents its recurrence. The most common adverse reactions to this product are bleeding, such as nosebleeds, gastrointestinal bleeding, and rectal bleeding, which also tend to cause anemia. There may also be gastrointestinal reactions such as abdominal pain, diarrhea, and dyspepsia. Note that it is contraindicated in people with severe renal insufficiency, significant active bleeding, and diseases or conditions with a significant risk of hemorrhage. Avoid combining any other anticoagulants while taking this product. Patients should use the drug under the supervision of a medical professional and strictly follow medical advice.